SynthesisFrontiers in oncology2024
Effectiveness of sigmoidoscopy or colonoscopy screening on colorectal cancer incidence and mortality: a systematic review and meta-analysis of randomized controlled trial.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 citations in OpenAlex.
- European Cancer Prevention Organization on cancer screening: an expert panel position paper.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Searching for Novel Molecular Prognostic Markers in Colorectal Cancer-The Tumor Suppressor Proteins p53 and PTEN.Biomedicines · 2026Article
- Knowledge, Beliefs, and Behaviors Regarding Colorectal Cancer Screening Among Koreans.Healthcare (Basel, Switzerland) · 2026Article
- Hemorrhoids and Rectal Cancer: A Systematic Review of Clinical Overlap, Diagnostic Misclassification, and Early Detection Strategies for Primary Care.Journal of multidisciplinary healthcare · 2026Review
- Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives.Exploration of targeted anti-tumor therapy · 2025Review
- Colonoscopy is not mammography: Challenges of applying the Duty of Candor.Endoscopy international open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We conducted a comprehensive analysis to compare colonoscopy and sigmoidoscopy with standard care or fecal immunochemistry regarding colorectal cancer incidence and mortality risk. Methods: Until August 2023, literature from PubMed, Embase, Web of Science, and Cochrane was systematically reviewed. We examined the impact of colonoscopy or sigmoidoscopy versus standard care on colorectal cancer outcomes, including incidence, cancer-specific mortality, and overall mortality. Results: Among 4,265 screened articles, data from seven randomized controlled trials (involving 663,319 participants) were analyzed. The intervention group (colonoscopy or sigmoidoscopy) consisted of 258,938 participants, while the control group received standard care or fecal immunochemical testing, totaling 404,381 participants, with both groups having average colorectal cancer risk, without confounders. Pooled analyses indicated a 20% reduction in colorectal cancer incidence (RR: 0.80, 95% CI: 0.77-0.83) and a 26% decrease in colorectal cancer mortality (RR: 0.74, 95% CI: 0.69-0.80) in the intervention group compared to standard care. All-cause mortality remained unchanged (RR: 1.03, 95% CI: 0.99-1.07). Subgroup analysis favored sigmoidoscopy in reducing colorectal cancer morbidity and mortality. Conclusion: This meta-analysis of randomized controlled trials underscores the effectiveness of colonoscopy and, notably, sigmoidoscopy in reducing colorectal cancer incidence and mortality among average-risk populations. In comparison to fecal immunochemical testing, both colonoscopy and sigmoidoscopy did not significantly impact colorectal cancer incidence and mortality in this population. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023460007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.